CA
NZ
UK
AU
IND
US
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a constituent of the Nasdaq-100, traded at US$224.41 as of 8 October 2026, against an analyst consensus price target of US$384, an implied upside of approximately +71.1%.
Amgen Inc. (NASDAQ:AMGN), a constituent of the Dow Jones Industrial Average, traded at US$413.08 as of 8 October 2026, against an analyst consensus price target of US$394.27, an implied upside of approximately -4.6%.
Ascendis Pharma (NASDAQ:ASND) traded at US$228.41 as of 8 October 2026, against an analyst consensus price target of US$315.61, an implied upside of approximately +38.2%.
BridgeBio Pharma (NASDAQ:BBIO) traded at US$66.50 as of 8 October 2026, against an analyst consensus price target of US$106.95, an implied upside of approximately +60.8%.
Biogen (NASDAQ:BIIB) traded at US$222.15 as of 8 October 2026, against an analyst consensus price target of US$229.84, an implied upside of approximately N/A.
BioMarin (NASDAQ:BMRN) traded at US$55.20 as of 8 October 2026, against an analyst consensus price target of US$89.52, an implied upside of approximately +62.2%.
BioNTech (NASDAQ:BNTX) traded at US$95.25 as of 8 October 2026, against an analyst consensus price target of US$123.79, an implied upside of approximately +30.0%.
BrightSpring Health Services (NASDAQ:BTSG) traded at US$63.80 as of 8 October 2026, against an analyst consensus price target of US$71.53, an implied upside of approximately +12.1%.
● The round backs an early-stage life-sciences business.
● The deal covers DevOps and agentic-AI tooling.
Please wait processing your request...